(Q37174391)

18 August 2017

1 reference

title

Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer (English)

1 reference

18 August 2017

1 reference

1 reference

1 reference

Max Mano

1

1 reference

18 August 2017

Yves Humblet

series ordinal

2

1 reference

18 August 2017

language of work or name

1 reference

27 May 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

415-425

1 reference

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Growth factors and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Single-molecule imaging of EGFR signalling on the surface of living cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Impact of EGFR expression on colorectal cancer patient prognosis and survival

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

FDA drug approval summary: panitumumab (Vectibix).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Molecular determinants of cetuximab efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1136

7 January 2021

Identifiers

DOI

10.1038/NCPONC1136

1 reference

18 August 2017

1 reference